Companies Push for Renewal of Anti-Bioterrorism Law

January 3, 2013
by Rebecca Adams
Congressional Quarterly


Drug and biotech manufacturers, public health advocates and venture capital investors who are concerned that Congress did not reauthorize a significant anti-bioterrorism bill in the 112th Congress are already lobbying lawmakers to pass it quickly in the new session that began Thursday.

“We’re starting all over again,” said Jeff Levi, president for the advocacy group Trust for America’s Health.